DoD Testosterone Screening Conflicts With Medical Guidelines
SkimNews Take
When a military screening mandate diverges from specialty society guidelines, the downstream cascade — treatment side effects, fitness disqualifications, fertility loss — can erode the very readiness the policy claims to protect.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Department of Defense announced a mandatory testosterone screening program for military servicemembers ages 30 and over, with Defense Secretary Pete Hegseth saying the decision to take supplements after a low result will be left to individual servicemembers.
- Endocrine Society guidelines recommend against routine population-level screening of asymptomatic men for hypogonadism and against routine supplementation in younger men with low testosterone — guidance the author says is at odds with the new DoD directive.
- The 2023 TRAVERSE trial found testosterone therapy was no worse than placebo for major cardiac events but showed higher incidence of acute kidney injury, atrial fibrillation, and pulmonary embolism in men taking testosterone replacement.
- The author's DOD-supported studies of TRICARE beneficiaries found higher rates of kidney stones and obstructive sleep apnea in military beneficiaries using testosterone supplementation, though the sleep apnea study also showed improved cardiovascular outcomes.
- Testosterone replacement therapy reduces testicle size and sperm counts, and both the American Urological Association and Endocrine Society caution against use in men planning to have children.
- The global testosterone therapy market grew from $18 million annually in the late 1980s to nearly $2 billion in 2025, growth the author attributes partly to direct-to-consumer marketing, online prescribing, and wellness influencers.
Why it matters: The DoD is launching a screening program that its own DOD-funded research has linked to elevated rates of kidney stones and sleep apnea, while national endocrine guidelines explicitly recommend against population-level screening of asymptomatic men. With Hegseth targeting all servicemembers 30 and over and leaving the treatment decision to individuals, hundreds of thousands of active-duty personnel could face fertility-affecting therapy without the personalized monitoring the author calls critical.
